98%
921
2 minutes
20
Background: Copy number variants (CNVs) associated with late-onset medical conditions are rare but important secondary findings in chromosomal microarray analysis (CMA) performed during pregnancy. Here, we critically review the cases at two tertiary centres to assess the criteria which guide the disclosure of such findings and develop a disclosure decision tool (DDT) aimed at facilitating disclosure decision. Parental decisions on receiving CNVs associated with risks for late-onset conditions were also recorded.
Methods: Prenatal CMAs in Hadassah and Shaare Zedek Medical Centers from November 2013 to October 2021 were reviewed for CNVs associated with late-onset conditions. The DDT proposed uses a five-parameter scoring system, which considers the severity, median age of onset, penetrance, understanding of genotype-phenotype correlation and actionability of the finding.
Results: Out of 16 238 prenatal CMAs, 16 (0.1%) harboured CNVs associated with late-onset conditions, 15 of which were disclosed. Outcome information was available on 13 of the 16 pregnancies, all of which continued to delivery.
Conclusions: Our suggested DDT will help clinicians to quantitatively weigh the variables associated with CNVs of this type and arrive at a well thought out clinical decision regarding disclosure. Although the prevalence of late-onset conditions as a major finding in the prenatal setup is low, it is expected to rise with the increasing use of non-invasive CMA testing and whole exome and genome sequencing.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/jmedgenet-2021-107890 | DOI Listing |
J Alzheimers Dis
September 2025
Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
Compared with more typical late-onset Alzheimer's disease (AD), the mechanisms of young-onset AD (YOAD; age of symptom onset <65 years) remain less understood. Using resting-state functional MRI data and dynamic causal modeling techniques, Sacu et al. demonstrate that individuals with YOAD (amnestic AD or posterior cortical atrophy) exhibit alterations in effective (i.
View Article and Find Full Text PDFCureus
August 2025
Surgery, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, MEX.
Introduction Early-onset colorectal cancer (EOCRC), defined as colorectal cancer diagnosed before the age of 50, has exhibited a sustained increase in incidence globally. In Mexico, this rising trend presents significant clinical and diagnostic challenges, particularly in younger patients who often lack traditional risk factors. This study aimed to describe and compare the epidemiological, clinical, histopathological, and therapeutic characteristics of EOCRC versus late-onset colorectal cancer (LOCRC) in a referral hospital in Mexico City.
View Article and Find Full Text PDFJ Genet Couns
October 2025
Department of Genetic Counseling, Graduate School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan.
Newborn screening (NBS) for Fabry disease (FD) is an effective way to identify individuals with FD before the onset of symptoms, enabling early therapeutic treatment. The classic form of FD typically begins in early childhood or later, but the late-onset form often develops in adulthood. However, FD-NBS identifies positive cases regardless of the expected timing of symptom onset.
View Article and Find Full Text PDFInt J Cardiol
September 2025
Department of Cardiovascular Surgery, State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang 110016, China. Electronic address:
Background: Atrial fibrillation and flutter (AF/AFL) are traditionally regarded as diseases of ageing, with most research focused on elderly populations. In contrast, early-onset AF/AFL (<65 years) is increasingly recognized as a potential marker of cardiomyopathy, yet its global burden remains poorly understood.
Methods: Using data from the Global Burden of Disease 2021 study, we analyzed trends in prevalence, incidence, disability-adjusted life years (DALYs), mortality, and average annual percentage change (AAPC) of AF/AFL among individuals aged 30-64 years from 1990 to 2021.
Adv Ther
September 2025
Sanofi, Gentilly, France.
Introduction: No head-to-head studies comparing the efficacy of avalglucosidase alfa (AVA) with cipaglucosidase alfa + miglustat (Cipa+mig) have been conducted in patients with late-onset Pompe disease (LOPD). Two indirect treatment comparisons (ITCs) were conducted to estimate the effects of AVA versus Cipa+mig.
Methods: ITCs were conducted using simulated treatment comparisons (STCs), adjusting for differences in prognostic factors and treatment effect modifiers.